InvestorsHub Logo
Followers 92
Posts 17181
Boards Moderated 0
Alias Born 09/06/2006

Re: Dan88 post# 403671

Wednesday, 09/22/2021 6:17:25 PM

Wednesday, September 22, 2021 6:17:25 PM

Post# of 688979

Remember some investors have been worried needlessly about the promised-but-yet seen publication based on DCVax-D trial. Now they have the answer: the granted patent, which is more comprehensive, broad and protective and much more significant than one or two papers published in Lancet or NEJM.


WOW.

The Direct trial reached the endpoints over 5 years ago. They actually did publish a paper a few years ago..

The patent is not "broad". It is patenting the 16 minute "method B" vs the previous (and soon expiring) patent that was broader.

Given that the US PTO did not allow the attempt to patent "13-20" minutes, and the previous method A was 20 minuets, it is hard to know if this really protects much of anything. Is 18 minutes better? Is 14 minutes better? And does anybody even know if 16 is better than 20?


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News